IJHSR

International Journal of Health Sciences and Research

| Home | Current Issue | Archive | Instructions to Authors |

Year: 2026 | Month: September | Volume: 16 | Issue: 9 | Pages: 293-297

DOI: https://doi.org/10.52403/ijhsr.20260931

Cervical Lymph Node Metastasis in Urinary Bladder Urothelial Carcinoma: A Case Report

Abhilash Panda1, Ahsan Ahmad2, Nikhil Ranjan3

1Senior Resident, Department of Urology, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, India
2Professor, Department of Urology, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, India
3Assistant Professor, Department of Urology, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, India

Corresponding Author: Dr Abhilash Panda

ABSTRACT

Background: Cervical lymph node metastasis is an unusual manifestation of bladder urothelial carcinoma.
Case Report: A 65-year-old man presented with painless intermittent gross hematuria. Imaging showed a 4.5 × 2.1 cm broad-based posterior bladder mass without distant metastasis or hydroureteronephrosis. Complete TURBT in January 2025 demonstrated high-grade urothelial carcinoma, T1. About 90 days later, recurrent hematuria was associated with a 5-cm right supraclavicular swelling. CT showed recurrent bladder tumor with perivesical fat infiltration, pelvic and retroperitoneal lymphadenopathy, and multiple right cervical nodes. The disease was staged cT3N3M1a. Cervical node biopsy showed malignant cells, with positivity for pancytokeratin, uroplakin and GATA3, supporting metastatic urothelial carcinoma. Systemic chemotherapy was planned, but the patient condition deteriorated and died.
Conclusion: A new cervical or supraclavicular mass in a patient with bladder cancer warrants prompt evaluation for metastatic disease.

Key words: urothelial carcinoma; bladder cancer; cervical lymph node metastasis; supraclavicular lymphadenopathy; uroplakin; GATA3; metastatic bladder cancer

[PDF Full Text]

Creative Commons Attribution License 4.0

This work is licensed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0) .